A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine

Leukemia and Lymphoma

Volumn 51, Issue 12, 2010, Pages 2258-2261

  Lim, Seah H ^a,b   Mcmahan, John ^a   Zhang, Jian ^b   Zhang, Yana ^b  

^a TEXAS ONCOLOGY   (United States)

^b Harrington Regional Medical Center Inc   (United States)

Author keywords

5 azacytidine failers; Clofarabine; MDS

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CLOFARABINE; LENALIDOMIDE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEHYDRATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; LOW DRUG DOSE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENINE NUCLEOTIDES; AGED; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; AZACITIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MYELODYSPLASTIC SYNDROMES; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 78650039737     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.527404     Document Type: Article

References (11)

1. Hellstrom-Lindberg E. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology Am Soc Hematol Educ Program 2005:161-166.
2. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003;102:2379-2386.
3. Kantarjian HM, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167-1173. (Pubitemid 46594149)
4. Faderl S, Garcia-Manero G, Estrov Z, et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2010;28:2755-2760.
5. Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-20-arabino- fluoro-20-deoxyadenosine. Proc Natl Acad Sci USA 1992;89:970-2974.
6. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro- 9-(2-deoxy-2-fluoro-b-D-arabinofuransosyl adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymaerases by its 50-triphosphate. Cancer Res 1992;51:2386-2394.
7. Xie C, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-b-D- arabinofuransosyl) adenine. Cancer Res 1996;56:3030-3037.
8. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000;96:3537-3543.
9. Zhang Y, Shahriar M, Zhang J, Ahmed SU, Lim SH. Clofarabine induces hypomethylation of DNA and expression of cancer-testis antigens. Leuk Res 2009;33:1678-1683.
10. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
11. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425.